48 results about "DNA binding site" patented technology

The present invention is directed to a novel Afx response element comprising the nucleotide sequence AACATGTT, said nucleotide sequence having a DNA binding site for the human fork head transkription factor Afx. The invention also relates to the use of the Afx response element in the screening for genes as diabetes drug targets and in the bioinformatic analysis of the human genome, said genes in turn being useful in other screening methods for compounds modifying the insulin receptor signaling pathway. A further aspect of the invention is a vector construct comprising the novel nucleotide sequence, a host cell transformed with said vector construct as well as the fusion protein expressed by said host cell.

Vector compositions comprising a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) promoter operably linked to a chimeric antigen receptor (CAR) are provided.

An artificial promoter system that can be fused upstream of any desired gene enabling reversible induction or repression of the expression of the gene at will in any suitable host cell or organisms by light is described. The design of the system is such that a molecule of the plant photoreceptor phytochrome is targeted to the specific DNA binding site in the promoter by a protein domain that is fused to the phytochrome and that specifically recognizes this binding site. This bound phytochrome, upon activation by light, recruits a second fusion protein consisting of a protein that binds to phytochrome only upon light activation and a transcriptional activation domain that activates expression of the gene downstream of the promoter.

Aptamer oligonucleotides specifically bind to the DNA binding site of proteins such as Sp1 and Sp1-related proteins which regulate the genes which encode costimulatory molecules such as CD28 and cytokines such as IL-2 and GMCSF. The oligonucleotides compete with the DNA-binding sites of regulatory proteins which specifically regulate molecules to modulate T-cell activation. This serves to modulate gene expression by preventing transcription of the gene. Aptamers are administered to provide therapies for diseases which involve aberrant T-cell activation such as psoriasis, Type I (insulin-dependent) diabetes mellitus, multiple sclerosis, autoimmune uveitis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease (Crohn's and ulcerative colitis), and septic shock and to regulate normal T-cell activation such as in allograft rejection.

Methods and compositions for immediately immunizing an individual against any molecule or compound are provided. The present invention is directed to an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target. The second binding sites are preferably thiolated aptamers that have the benefit of increased stability, resistance to degradation and longer circulating half life. Methods of making and using pharmaceutical compositions including immunity linker molecules having a thiolated aptamer are also provided.

A multispecific reagent has at least one first binding site for a cell surface receptor which requires multimeric ligand binding to be stimulated. The reagent possesses a second binding site for a target antigen which is expressed on the same cell as the cell surface receptor.

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

An adenoviral vector which expresses a dominant negative form of Stat3 called Stat3-EVA for the treatment of non-small cell lung carcinoma. This construct has two mutations in the DNA binding site of Stat3 which prevents binding to DNA but has no effect on tyrosine phosphorylation or dimerization.

The invention provides a transcription factor binding site prediction algorithm and device across transcription factors. The method comprises the following steps: 1, predicting amino acids capable ofbinding to DNA in all transcription factors, namely DNA binding sites, wherein the predicted DNA binding sites are mainly used for measuring contributions of labeled data of different transcription factors in a target transcription factor model training process; 2, learning a representation vector of transcription factors from a sequence composed of the predicted DNA binding sites; 3, learning thehigh-order dependency relationship of the DNA fragments from the histone modification characteristics of the DNA fragments; 4, learning the low-order dependency relationship of the DNA fragments fromthe sequence characteristics of the DNA fragments; 5, splicing the learned vector representation of the transcription factors, the high-order dependency relationship and the low-order dependency relationship of the DNA fragments into a feature vector, inputting the feature vector into a multilayer perceptron to classify the target DNA fragments, and judging whether the target DNA fragments are binding sites of the target transcription factor or not.

The invention provides a method for separating DNA (deoxyribonucleic acid) binding protein and accurately positioning DNA binding site, which comprises the following steps: DNA binding protein separation: carrying out PCR (polymerase chain reaction) amplification on a DNA segment to be researched by using biotin-labeled primers, sequentially adding nucleoprotein or cytoplast protein and avidin-coated magnetic beads, co-incubating, washing off nonspecific binding protein, and adding SDS (sodium dodecylsulfate) to denature and release the protein; and protein DNA binding site positioning: by using the DNA segment to be researched as a template, carrying out PCR reaction by using different primers to obtain overlapping DNA segments, and positioning the DNA binding site of the isolated protein according to the affinity difference of the overlapping DNA segments for the isolated protein.

The invention relates to an analysis method for the geometrical structure characteristics of DNA binding protein interface, belonging to the technical field of biological computing. The present invention first derives proteins-DNA binding site information from proteins-DNA complex dataset; and then based on the protein-DNA Binding Site Information, residue Morphological Index and Spatial Environment of proteins-DNA Binding Sites are determined; finally, the morphological index and spatial environment of the identified protein-DNA binding sites are used as feature vectors to classify the obtained feature vectors by using classification model. As the binding specificity of double-stranded DNA binding protein (DSBs) and single-stranded DNA binding proteins (SSBs) is analyzed from the angles of the morphological structure of the residues and the characteristics of the space environment, the invention is conducive to the in-depth understanding of the proteins, and the binding specificity ofthe double-stranded DNA binding proteins and the single-stranded DNA binding proteins is analyzed. Based on the DNA binding mechanism, the present invention can also be applied to proteins-RNA, protein-Protein and other fields.

The invention discloses a novel purpose of a DNA binding site CTCF_113 of a multifunctional transcriptional regulatory factor CTCF, i.e., the application thereof to prevention of a kit for early diagnosis of colorectal carcinoma. The binding site has the nucleotide sequence shown as SEQ ID NO:1. The accuracy of the CTCT binding site provided by the invention for detecting rectal adenoma and colorectal cancer is obviously higher than that of the reported DNA methylation molecular markers; the DNA binding site of the CTCF can be likely to become a biomarker for tumor treatment effect monitoring, prognosis effect evaluation and tumor molecular subtyping (such as CIMP subtyping). Generally, the invention provides a novel idea for finding the more effective tumor early stage diagnosis, treatment effect monitoring, prognosis effect evaluation and molecular subtyping molecular markers, and has the important significance on tumor prevention and treatment.

The invention discloses novel application of a DNA binding site CTCF_55 of a multifunctional transcriptional regulation factor CTCF, and particularly relates to application of the DNA binding site CTCF_55 in preparation of a kit for early diagnosis of a colorectal tumor. The nucleotide of the binding site is shown as SEQ ID NO: 1. The accuracy of the CTCF binding site provided by the invention for detecting colorectal adenomas or a colorectal cancer is obviously higher than that of a reported DNA methylated molecular marker; furthermore, the DNA binding site of the CTCF may be a biological marker for monitoring the tumor treatment effect, estimating the prognosis effect and tumor molecular parting (such as CIMP parting). In conclusion, the invention provides a new idea for searching a more effective molecular marker for early diagnosis of the tumor, monitoring of the treatment effect, estimation of the prognosis effect and the molecular parting, and the application has important significance for prevention and treatment of the tumor.

The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.